SCHEMBL13600098

SCHEMBL13600098

Cc1nn(-c2cnccn2)c(C)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
CYP1A2 P05177 3/20 0.38
CYP17A1 P05093 2/20 0.38
TSHR P16473 1/20 0.36
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
KDM4E B2RXH2 4/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TGFBR1 P36897 1/20 0.32
EGLN2 Q96KS0 1/20 0.31
CNR1 P21554 1/20 0.31
HSP90AA1 P07900 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13741414 0.82 CCNA2 (0.41) CA12CA1CA2CA9CCNA2
SCHEMBL13600097 0.78 CCNA2 (0.41) CA12CA1CA2CA9CCNA2
SCHEMBL18949733 0.74 ALDH1A1 (0.55) CCNA2CDK2ALDH1A1HPGDALOX15
SCHEMBL3269737 0.72 PDE4D (0.56) ALDH1A1KDM4E
SCHEMBL29577243 0.70 SMN1; SMN2 (0.50) CA12CA1CA2CA9TSHR
SCHEMBL28729454 0.70 SMN1; SMN2 (0.50) CA12CA1CA2CA9TSHR
SCHEMBL18949738 0.69 TSHR (0.49) CA12CA1CA2CA9TSHR
SCHEMBL13861272 0.67 SMN1; SMN2 (0.39) CCNA2CDK2CYP1A2CYP17A1ALDH1A1
SCHEMBL18949731 0.67 CA12 (0.47) CA12CA1CA2CA9CCNA2
SCHEMBL13600075 0.67 CA12 (0.41) CA12CA1CA2CA9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625905-B2 Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists ROCHE PALO ALTO LLC (US) 2009-12-01 US disclosed
US-20080103125-A1 Heterocylic antiviral compounds ROCHE PALO ALTO LLC 2008-05-01 US disclosed
US-20080103125-A1 Heterocylic antiviral compounds ROCHE PALO ALTO LLC 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103125-A1 Heterocylic antiviral compounds CCR5, ACKR3, CXCR3 CA12 4592/4885CA1 4588/4885CA2 4475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.